RLAY: Bull Flag detected on 28 Aug 2026

RLAY is forming a bull flag pattern with structure score of 15.0 and overall setup score of 72.4 out of 98, indicating strong pattern geometry. The stock trades at $19.42, positioned between key support at $17.71 and near-term resistance at $20.79. Volume ratio of 1.08x is slightly elevated above the 20-day average, suggesting moderately healthy participation. Breakout score of 11.2 reflects good technical momentum readiness. RSI at 48.84 shows neutral positioning with room to run. The pattern sits in a bullish market regime (0.61) with the healthcare sector in a strong bullish trend (0.84).

Relay Therapeutics made important progress in early 2026, highlighted by promising data supporting further development for the zovegalisib plus atirmociclib triplet combination in frontline breast cancer. The company received FDA Breakthrough Therapy designation for zovegalisib in PIK3CA-mutant, HR+/HER2- advanced breast cancer. Recent earnings-beat optimism and strong share price run suggest expectations are already elevated. The fresh US$175,000,000 equity raise and expanded share authorization underline that Relay is still funding an unprofitable model, with future financing and trial risk in view. Stock has gained 39.71% in three months on anticipated Phase 3 trial progress.

A successful breakout above $20.79 resistance would target $20.06 conservatively, with potential for higher advances if volume remains elevated. Historical breakout probability of 75.13% suggests favorable odds for pattern completion. Invalidation occurs on close below key support at $17.71, representing a 8.8% downside risk from current levels. Volume confirmation is critical—breakouts on above-average volume (above 2.2M shares) yield higher success rates. MACD histogram at -0.1198 shows slight bearish divergence, requiring strengthening momentum on the breakout move to validate the pattern.

The Q2 2026 update serves as a near-term sentiment check, with focus on zovegalisib's Phase 3 trajectory and pipeline execution as the main catalyst. Key risk: Q3 earnings have not yet been scheduled, leaving upcoming data gaps. Clinical-stage biotech faces binary trial risk—any negative zovegalisib Phase 3 updates or competitive setbacks could trigger sharp reversals. Beta of 0.93 provides moderate downside protection but offers limited leverage. MACD histogram at -0.1198 suggests early momentum deterioration despite bullish price action. Elevated expectations mean even modest guidance misses could amplify disappointment.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.